This suggests that passive immunization with tau antibodies can be a practical therapeutic target and which the CSF volume of p-tau262/356 or of the microtubule binding area (MTBD) can serve as a practical biomarker of tau pathology to watch tau therapeutics in clinical trials. Their story laid t